PT-141 (Bremelanotide)
FDA-approved bremelanotide is labeled for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Any other use is clinician-directed and off-label.
How it is offered
Added at Clinician Discretion
Pricing
Offered alongside care. Any charge is shown to you before you authorize it.
PT-141 requires a written prescription from a licensed clinician. The FDA-approved product is labeled only for premenopausal women with hypoactive sexual desire disorder. Compounded bremelanotide is not FDA-approved or evaluated for safety, effectiveness or quality. Evidence standards.
Start Your Assessment →What Is PT-141 (Bremelanotide)?
Bremelanotide, sold as Vyleesi, is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It acts on melanocortin receptors in the brain rather than on blood flow.
Use outside that indication is off-label, and we review other causes of low desire first.
Good to Know
- Prescribed only after a clinician reviews your history.
- Dose and course are set by your clinician, not by you.
- Results vary, and we do not promise outcomes.
Who It Is For
Eligibility
Often a Good Fit If
- ✓Premenopausal women with persistent, distressing low sexual desire that is not explained by another cause
- ✓Other uses only when your clinician judges them reasonable and explains that they are off-label
- ✓Blood pressure that is well controlled
- ✓A reviewed medication list and a review of other causes, such as sleep, mood and hormones
Not Prescribed If
- —Uncontrolled high blood pressure, or known cardiovascular disease
- —Pregnancy, or trying to conceive
- —Low desire explained by a medication, relationship or medical condition that has not been addressed
- —Prior serious hypersensitivity to bremelanotide
Read Before You Decide
Key Risks, Stated Plainly
In trials, the most common effect was nausea, followed by flushing, headache and injection-site reactions. Bremelanotide can raise blood pressure temporarily after a dose, and repeated use can cause darkening of the skin or gums that may not fully reverse.
Contact care the same day for
Chest pain, severe headache, a sustained rise in blood pressure, fainting, signs of allergic reaction, or new patches of darkened skin.
What Is Measured
Blood Pressure
Checked before the first dose and reviewed at follow-up.
Desire and Distress
Your own reports, recorded at each check-in.
Contributing Causes
Thyroid, iron, sleep, mood and medications are reviewed first.
Skin and Tolerance
Reviewed for nausea and for any skin changes.
A Clearer Path Forward
How Clinicians Review Your Response
You and Your Clinician Look at the Same Data
Symptoms you report, laboratory results and, if you connect one, wearable trends are reviewed together before any change.
A Physician-Led Review Every 90 Days
Included in your monthly price. Your clinician decides whether to continue, adjust the dose, change course or stop.
Clinical Judgment Decides
Measurements inform the decision. They do not make it, and no dashboard changes your dose on its own.
Your Care Sequence
01
Questionnaire
Share your history and goals in about ten minutes. No card required.
02
Video Visit
Meet your clinician to review your history, your blood pressure and other possible causes.
03
Delivery
If prescribed, medication ships from a licensed pharmacy, cold-chain when required, with supplies.
04
Ongoing Care
Messaging between visits and a physician-led review every 90 days, included with your care.
Common Questions About PT-141 (Bremelanotide)
Is PT-141 FDA-Approved?+
Bremelanotide is FDA-approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Compounded bremelanotide is not FDA-approved, and use outside the approved indication is off-label.
Is It Used for Men?+
Sometimes, at a clinician's discretion. The evidence in men is limited, and we say so before prescribing.
How Is It Taken?+
By subcutaneous injection, as needed rather than daily. Your clinician explains timing and limits on how often it can be used.
Why Do You Look at Other Causes First?+
Low desire is often related to thyroid function, iron, sleep, mood or medications. Treating those can resolve it without a prescription.
Still unsure? Message the care team before you join. No account needed.
The Mechanism
The Proposed Mechanism
Melanocortin Receptors
Bremelanotide activates melanocortin receptors in the brain involved in sexual desire and arousal.
Central, Not Vascular
Unlike PDE5 inhibitors, it acts on the central nervous system rather than on blood flow.
For Readers Who Want More
Deeper Evidence
What We Can and Cannot Tell YouEvidence and regulatory status+
What the Evidence Supports
In two randomized trials in that population, bremelanotide improved measures of desire and reduced related distress compared with placebo, and it is FDA-approved for that use.
What It Does Not (Yet)
The trials did not study men, postmenopausal women or compounded formulations, and effects were modest on average.
Badge definitions and FDA category sourcing are on the Science page.
Selected Studies
Kingsberg et al., Obstetrics & Gynecology, 2019 (RECONNECT)
In premenopausal women with hypoactive sexual desire disorder, bremelanotide improved desire and reduced related distress versus placebo. Effects were modest on average.
See Whether PT-141 Is Appropriate for You
Ten minutes, no card, reviewed by a clinician.